Find a Doctor
Michael Shafique, MD
Locations: Moffitt Cancer Center
Cancer Focus: Lung Cancer , Mesothelioma , Neuroendocrine Tumor , Pancoast Tumor , Thymoma
Dr. Shafique earned his MD degree at the University of Virginia, School of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center and, most recently, a Hematology and Oncology Fellowship at University of South Florida/Moffitt Cancer Center. Dr. Shafique devotes the majority of clinical time treating lung cancer. However, he will also cares for patients with a wide spectrum of diagnoses as part of early phase clinical trials.
Education & Training
- Internal Medicine
- University of South Florida - Hematology and Oncology
- Duke University Medical Center - Internal Medicine
- University of Virginia School of Medicine - MD
CLINICAL TRIAL 20163
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non©\Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature©\driven Analysis
Intervention: Alimta (Pemetrexed); MK-3475 (Keytruda); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()
CLINICAL TRIAL 19746
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors
Intervention: Avelumab (); M3814 (); MSB00100718C (Avelumab)
CLINICAL TRIAL 20258
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Intervention: AMV564 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 20576
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
Intervention: MLN4924 (Pevonedistat); Paraplatin (carboplatin); Pevonedistat (); Taxol (paclitaxel); carboplatin (); paclitaxel ()
- Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543.
- Saltos A, Shafique M, Chiappori A. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Front Oncol. 2020 Jul.10:1074. Pubmedid: 32766139. Pmcid: PMC7378389.
- Puri S, Shafique M. Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs Context. 2020 Jan.9. Pubmedid: 32158484. Pmcid: PMC7048109.
- Gray JE, Saltos AN, Tanvetyanon T, Haura EB, Creelan BC, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov.25(22):6623-6632. Pubmedid: 31409616. Pmcid: PMC7234799.
- Shafique M, Tanvetyanon T. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opin Biol Ther. 2019 Mar.19(3):225-232. Pubmedid: 30657338.
- Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, Hogue D, Soliman H, Khong H, Han HS. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. Oncologist. 2019 Jul.24(7):887-e416. Pubmedid: 30996012. Pmcid: PMC6656474.
- Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res. 2018 May.10:931-940. Pubmedid: 29760563. Pmcid: PMC5937504.
- Puri S, Shafique M, Gray JE. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. CURR TREAT OPTION ON. 2018 Jun.19(8):39. Pubmedid: 29931587.
- Shafique MR, Lee MC, Han HS. Treatment of the Pregnant Patient with Breast Cancer. South Med J. 2017 Oct.110(10):627-631. Pubmedid: 28973702.
- Turza KC, Shafique M, Lobo PI, Sawyer RG, Keith DS, Brayman KL, Agarwal A. Infectious complications in living-donor kidney transplant recipients undergoing multi-modal desensitization. Surg Infect (Larchmt). 2014 Jun.15(3):182-186. Pubmedid: 24773230. Pmcid: PMC4696441.
- Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Tr. 2014 Feb.20(2):257-263. Pubmedid: 24269380. Pmcid: PMC4140655.
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.